ALX Oncology Holdings Inc
Follow $ALXO
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $ALXO by emailVeridion Score
BETAMEDIUM CONF · 5 of 6 factors measuredsnapshot unavailable for ALXO. Cause unavailable.
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is ALXO moving today?
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
ALXO overview
Related filings and maps
Congress activity in ALXO
No receipt-qualified Congressional disclosure is present for ALXO in the cached public ledger.
ALXO contract awards, year to date.
Public federal awards linked to this ticker.
ALXO lobbying filings, year to date.
Registered lobbying filings matched to ALX Oncology Holdings Inc.